journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thrombosis and Haemostasis: JTH

journal
https://www.readbyqxmd.com/read/29790645/fibrinogen-prothrombin-time-derived-method-is-not-useful-in-patients-anticoagulated-with-low-molecular-weight-heparins-or-rivaroxaban
#1
C Duboscq, M Martinuzzo, J M Ceresetto, M Lopez, L Barrera, J Oyhamburu, G Stemmelin
BACKGROUND: Fibrinogen prothrombin time derived method (FIBPT-d) with photo-optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). OBJECTIVE: To compare fibrinogen results obtained by Clauss method (FIB C) and FIBPT-d with two thromboplastins in anticoagulated patients. POPULATION: 295 consecutive anticoagulated patients: 99 vitamin K antagonist (VKA), 49 unfractionated heparin (UFH), 47 LMWH, 50 rivaroxaban and 50 dabigatran; and 100 healthy controls (NC)...
May 23, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29781099/flow-cytometric-analysis-of-extracellular-vesicle-subsets-in-plasma-impact-of-swarm-by-particles-of-non-interest
#2
S F W M Libregts, G J A Arkesteijn, A Németh, E N M Nolte-'t Hoen, M H M Wauben
BACKGROUND: Extracellular vesicles (EVs) in plasma are increasingly recognized as potential biomarkers. EV analysis for diagnostic purposes should be robust and should allow analysis of EV subsets in a wide range of abundance and in a large number of patient samples. Flow cytometry offers possibilities to meet these criteria as it allows multi-parameter analysis of individual EVs. However, analysis of plasma EVs is challenging due to their size and heterogeneity and the presence of other submicron-sized particles in plasma that could interfere in EV-analysis...
May 20, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29779246/regulation-of-plasminogen-activation-on-cell-surfaces-and-fibrin
#3
REVIEW
Tetsumei Urano, Francis J Castellino, Yuko Suzuki
The fibrinolytic system dissolves fibrin and maintains vascular patency. Recent advances in imaging analyses allowed visualization of the spatiotemporal regulatory mechanism of fibrinolysis, as well as its regulation by other plasma haemostasis cofactors. Vascular endothelial cells (VECs) retain tissue-type plasminogen activator (tPA) after secretion and maintain high plasminogen (plg) activation potential on their surfaces. As in plasma, the serpin, plasminogen activator inhibitor type 1 (PAI-1), regulates fibrinolytic potential via inhibition of the VEC surface-bound plg activator, tPA...
May 20, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29777567/karl-landsteiner
#4
EDITORIAL
F R Rosendaal, P H Reitsma
No abstract text is available yet for this article.
May 18, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29772108/reduced-dose-direct-oral-anticoagulants-in-the-extended-treatment-of-venous-thromboembolism-a-systematic-review-and-meta-analysis
#5
Lakshman Vasanthamohan, Kochawan Boonyawat, Chatree Chai-Adisakopha, Mark Crowther
BACKGROUND: Extended duration anticoagulation is beneficial for preventing recurrent venous thromboembolism (VTE). Reduced dose direct oral anticoagulants (DOACs) may be preferable if they preserve efficacy and cause less bleeding. We conducted a systematic review and meta-analysis of trials comparing reduced dose DOACs with full dose DOACs and aspirin or placebo in the extended phase of VTE treatment. METHODS: A literature search was conducted using the MEDLINE, EMBASE and CINAHL databases supplemented by hand-searching...
May 17, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29771476/questioning-the-use-of-an-age-adjusted-d-dimer-threshold-to-exclude-venous-thromboembolism-reply
#6
S Takach Lapner, Jim A Julian, Lori-Ann Linkins, Shannon Bates, Clive Kearon
In a recent analysis[1], we questioned the validity of using a progressively higher D-dimer to define a positive test as the age of patients with suspected venous thromboembolism (VTE) increased over 50 years (termed "age-adjusted D-dimer" interpretation). We hypothesized that the benefits of age-adjusted D-dimer interpretation compared with using a conventional threshold of 500 ug/L in patients of all ages were due to a non-specific increase in the average D-dimer threshold used to classify a test as positive...
May 17, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29766637/subtype-specific-clinical-and-prognostic-relevance-of-tumor-expressed-f5-and-regulatory-f5-variants-in-breast-cancer-the-cocav-study
#7
Mari Tinholt, Øystein Garred, Elin Borgen, Elsa Beraki, Ellen Schlichting, Vessela Kristensen, Kristine Kleivi Sahlberg, Nina Iversen
BACKGROUND: Tumor expression of certain coagulation factors have been linked to cancer progression. Single nucleotide polymorphisms (SNPs) in F5 (encoding the FV protein) have been found associated with breast cancer, however, the role of coagulation factor V (FV) in cancer pathogenesis remains undiscovered. OBJECTIVES: We aimed to investigate the clinical significance of FV and the regulatory role of F5 gene variants in breast cancer. PATIENTS/METHODS: A Scandinavian 503-sample breast cancer cohort and three public breast cancer data sets (GOBO, TCGA, and KM plotter) were used to determine associations between F5 gene expression (tumor-specific), circulating FV, F5 SNPs, clinical characteristics, and breast cancer survival...
May 16, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29763979/extended-international-normalized-ratio-testing-intervals-for-warfarin-treated-patients
#8
G D Barnes, X Kong, D Cole, B Haymart, E Kline-Rogers, S Almany, M Dahu, M Ekola, S Kaatz, J Kozlowski, J B Froehlich
BACKGROUND: A prior single center randomized trial suggested that patients with stable INR values could safely receive INR testing as infrequently as every 12 weeks. OBJECTIVE: To test the implementation success of an extended INR testing interval for stable warfarin patients in a practice-based, multi-center collaborative of anticoagulation clinics. METHODS: At six anticoagulation clinics, patients were identified as being eligible for extended INR testing based on prior INR value stability and minimal warfarin dose changes between 2014 and 2016...
May 15, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29762905/pharmacokinetics-and-the-transition-to-extended-half-life-factor-concentrates-communication-from-the-ssc-of-the-isth
#9
Margaret V Ragni, Stacy E Croteau, Massimo Morfini, Marjon H Cnossen, Alfonso Iorio
Extended half-life proteins (EHL) are increasingly used in clinical practice, but there is no standardized approach to sampling, interpretation, and implementation of pharmacokinetics (PK) data to maximize treatment benefit. The goal of EHL treatment is to attain a trough level sufficient to protect against spontaneous bleeds and reduce infusion frequency and limitations on individual activity and lifestyle. Performing classical PK assessments requires multiple blood samples which is burdensome for patients and providers...
May 15, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29761865/what-the-neighbor-says
#10
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
May 15, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29758126/abrogating-fibrinolysis-does-not-improve-bleeding-or-rfviia-rfviii-treatment-in-a-non-mucosal-venous-injury-model-in-haemophilic-rodents
#11
Rikke Stagaard, Matthew J Flick, Barbara Bojko, Krzysztof Goryński, Paulina Z Goryńska, Carsten D Ley, Lisbeth H Olsen, Tom Knudsen
BACKGROUND: Fibrinolysis may exacerbate bleeding in haemophilia A (HA). Accordingly, antifibrinolytics have been used to help maintain haemostatic control. While antifibrinolytic drugs have been proven effective in the treatment of mucosal bleeds in the oral cavity, their efficacy in non-mucosal tissues remain an open question of significant clinical interest. OBJECTIVE: To determine whether inhibiting fibrinolysis improves the outcome in non-mucosal haemophilic tail vein transection (TVT) bleeding models, and to determine whether a standard ex vivo clotting/fibrinolysis assay can be used as a predictive surrogate for in vivo efficacy...
May 14, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29754426/venous-thromboembolism-in-cancer-patients-receiving-neoadjuvant-chemotherapy-a-systematic-review-and-meta-analysis
#12
M Di Nisio, M Candeloro, A W S Rutjes, E Porreca
BACKGROUND: Venous thromboembolism (VTE) is a frequent complication in cancer patients receiving adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. OBJECTIVES: This systematic review evaluated the incidence of VTE in patients with cancer receiving neoadjuvant treatment. METHODS: MEDLINE and EMBASE databases were searched from inception to October 2017. Search results were supplemented with screening of conference proceedings of the American Society of Clinical Oncology (2009-2016) and the International Society of Thrombosis and Haemostasis (2003-2016)...
May 13, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29753308/rivaroxaban-for-thromboprophylaxis-among-patients-recently-hospitalized-for-acute-infectious-diseases-a-subgroup-analysis-of-the-magellan-study
#13
Kevin P Cohoon, Yoriko De Sanctis, Lloyd Haskell, Robert D McBane, Theodore E Spiro
BACKGROUND: Despite the well-established association between infection and venous thromboembolism (VTE), there are few data specifically assessing the efficacy and safety of the VTE prophylaxis strategies for patients hospitalized for acute infectious diseases. OBJECTIVES: Estimate incidence of VTE and bleeding outcomes comparing prolonged prophylaxis with rivaroxaban 10 mg daily for 35 days with enoxaparin 40 mg daily for 10 days. PATIENTS/METHODS: A subgroup analysis of patients hospitalized for acute infectious diseases in the MAGELLAN trial was performed...
May 12, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29742318/a-comparative-analysis-of-different-automated-von-willebrand-factor-glycoprotein-ib-binding-activity-assays-in-well-typed-von-willebrand-disease-patients
#14
I Vangenechten, K Mayger, P Smejkal, O Zapletal, J J Michiels, G W Moore, A Gadisseur
BACKGROUND: von Willebrand Disease (VWD) is an inherited bleeding disorder caused by quantitative (type 1, 3) or qualitative (type 2) von Willebrand factor (VWF) defect. VWD diagnosis and classification require numerous laboratory tests. VWF: Glycoprotein Ib (GPIb)-binding activity assays are used to distinguish type 1 from type 2 VWD. OBJECTIVES: Three different automated VWF:GPIb-binding activity assays were compared. PATIENTS AND METHODS: BC-VWF:RCo (Siemens Healthcare Diagnostics), HemosIL® VWF:RCo (Instrumentation Laboratory) and INNOVANCE® VWF:Ac (Siemens Healthcare Diagnostics) were performed in a well typed VWD cohort (n=142)...
May 9, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29734527/evolutionary-conservation-of-the-allosteric-activation-of-factor-viia-by-tissue-factor-in-lamprey-reply
#15
D L Beeler, W C Aird, M A Grant
We have read with interest the letter by Olsen and colleagues in response to our recent article [1]. Therein, we reported the cloning of full-length tissue factor (Tf) and factor VIIa (FVIIa) cDNAs from lamprey Petromyzon marinus, and characterization of structural features in the proteins. Using constructed models of lamprey (Pm) tissue factor soluble extracellular-domain (sTF) and factor VIIa (sTF/FVIIa) complex, we assessed the conservation of allosteric TF-mediated stabilization of the FVIIa heavy chain (FVIIa-hc)...
May 7, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29734520/routine-measurements-of-factor-viii-activity-and-inhibitor-titer-in-the-presence-of-emicizumab-utilizing-anti-idiotype-monoclonal-antibodies
#16
Keiji Nogami, Tetsuhiro Soeda, Tomoko Matsumoto, Yoshiki Kawabe, Takehisa Kitazawa, Midori Shima
BACKGROUND: Emicizumab is an anti-factor (F)IXa/X bispecific monoclonal antibody (mAb), mimicking the Factor (F)VIIIa cofactor activity. Emicizumab does not require activation by thrombin and its shortening effect on the activated partial prothrombin time (aPTT) is more pronounced than that of Factor (F)VIII. aPTT-based FVIII activity (FVIII:C) and FVIII inhibiter titer measurements are influenced by the presence of emicizumab. AIM: To establish a reliable aPTT-based assay to measure FVIII in the presence of emicizumab...
May 7, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29734512/correction-of-a-dominant-negative-von-willebrand-factor-multimerization-defect-by-small-interfering-rnas-mediated-allele-specific-inhibition-of-mutant-von-willebrand-factor
#17
A de Jong, R J Dirven, J A Oud, D Tio, B J M van Vlijmen, J Eikenboom
BACKGROUND: Treatment of the bleeding disorder von Willebrand disease (VWD) focusses on increasing von Willebrand factor (VWF) levels through administration of desmopressin or VWF-containing concentrates. Both therapies leave production of mutant VWF unhindered which may have additional consequences, like thrombocytopenia in VWD type 2B, competition between mutant and normal VWF for platelet receptors, and potential development of intestinal angiodysplasia. Most VWD is caused by dominant-negative mutations in VWF and we hypothesize that diminishing expression of mutant VWF positively affects VWD phenotypes...
May 7, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29733498/risk-stratification-for-the-development-of-venous-thromboembolism-in-hospitalized-patients-with-cancer
#18
Arabesque Parker, Erica Peterson, Agnes Y Y Lee, Carine de Wit, Marc Carrier, Gina Polley, Julia Tien, Cynthia Wu
INTRODUCTION: The Khorana score is a validated risk assessment score for estimating the risk of symptomatic venous thromboembolism (VTE) in outpatients with cancer. The objective of this study was to assess the Khorana score for predicting the development of VTE in cancer patients during hospital admission. METHODS: We conducted an analysis of consecutive, adult cancer patients hospitalized for medical reasons between January and June 2010 in 3 academic medical centers...
May 7, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29733497/hemostasis-biomarkers-and-incident-cognitive-impairment-the-regards-study
#19
S R Gillett, L A McClure, P W Callas, E L Thacker, F W Unverzagt, V G Wadley, A J Letter, M Cushman
BACKGROUND: Vascular risk factors are associated with cognitive impairment, a condition with substantial public health burden. We hypothesized that hemostasis biomarkers related to vascular disease would be associated with risk of incident cognitive impairment. METHODS: We performed a nested case control study including 1,082 participants with 3.5 years of follow-up in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a longitudinal cohort study of 30,239 black and white Americans ≥45 years old...
May 7, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29733495/questioning-the-use-of-an-age-adjusted-d-dimer-threshold-to-exclude-venous-thromboembolism-comment
#20
LETTER
Noémie Kraaijpoel, Myrthe M A Toorop, Patrick M Bossuyt, Frederikus A Klok, Harry R Büller, Nick van Es
D-dimer testing is a cornerstone of the diagnostic management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Over the past decade, the threshold used to exclude venous thromboembolism (VTE) has transitioned from a fixed threshold to an age-adjusted threshold [1] and, more recently, to a clinical probability dependent threshold [2]. This transition intended to increase the proportion of patients in whom imaging can be withheld, without jeopardizing safety. In a post-hoc analysis of two prospective diagnostic management studies, Takach Lapner and colleagues found no differences in diagnostic accuracy between an age-adjusted, an increased fixed, and an inverse age-adjusted D-dimer threshold [3]...
May 7, 2018: Journal of Thrombosis and Haemostasis: JTH
journal
journal
20181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"